Monocyte Chemoattractant Protein-1 2518A/G Polymorphism

Association of Monocyte Chemoattractant Protein-1 (MCP-1)2518A/G Polymorphism With Proliferative Diabetic Retinopathy in Northern Chinese Type 2 Diabetes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02077127

Acronym

MCP-1

Enrollment

1043

Registered

2014-03-04

Start date

2011-09-30

Completion date

2013-04-30

Last updated

2014-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy

Brief summary

The pathogenesis of proliferative diabetic retinopathy (PDR) remains poorly understood. Recent studies have implicated that monocyte chemoattractant protein-1 (MCP-1) is associated with diabetic microvascular or macrovascular complications. However, the relationship between SNP polymorphism c.2518A/G in the MCP-1 gene with diabetic retinopathy remains controversial. In the present study, we evaluated the association of a single nucleotide polymorphism (SNP) in the MCP-1 gene with diabetic retinopathy (DR) and diabetic macular edema (DME) in Chinese population from Southern China with type 2 diabetes.

Detailed description

The association between polymorphism of MCP-1 c.2518A/G and DR had been reported in Japan and Korea, but their opinion were inconsistent. However there is no report in China so far. This study was designed to clarify the relationship of polymorphism of MCP-1 c.2518A/G with type 2 diabetes with or without DR. The relationship between MCP-1 c.2518A/G and different stage of DR has also been studied.This article proved that the MCP-1 c.2518G/G genotype is a susceptibility gene for DR in Chinese type 2 diabetic patients, especially the High-risk PDR. There is no association with DME and c.2518G/G.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

41 Years to 68 Years

Healthy volunteers

Inclusion criteria

* Type 2 diabetic retinopathy * age at diagnosis ≥30 years and a known duration of diabetes of ≥5 years.

Exclusion criteria

* eyeball atrophy * epimacular membrane * age-related macular degeneration (ARMD) * intravitreal injection medicine * vitreous hemorrhage

Design outcomes

Primary

Measure	Time frame	Description
Genetic association	1 year	age at diagnosis of diabetes ≥30 years and a known duration of diabetes of ≥5 years.

Countries

China

Outcome results